Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: Regression of visceral amyloid following liver transplantation

European Journal of Nuclear Medicine

Volumn 25, Issue 7, 1998, Pages 709-713

  Rydh, Anders ^a,c   Suhr, Ole ^a   Hietala, Sven Ola ^a   Åhlström, Katrine Riklund ^a   Pepys, Mark B ^b   Hawkins, Philip N ^b  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Amyloidosis; Liver transplantation; Polyneuropathy; Scintigraphy; Serum amyloid P component

Indexed keywords

IODINE 123; PREALBUMIN; SERUM AMYLOID P; TRACER;

ADRENAL GLAND; ADULT; AMYLOID NEUROPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; KIDNEY; KIDNEY FAILURE; LIVER TRANSPLANTATION; MALE; PATIENT MONITORING; REMISSION; SCINTIGRAPHY; SPLEEN; TREATMENT OUTCOME; VISCERA; WHOLE BODY SCINTISCANNING;

ADULT; AMYLOID NEUROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; TREATMENT OUTCOME;

EID: 0031815275     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050273     Document Type: Article

References (22)

1. Pepys MB. Amyloidosis. In: Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. Oxford: Oxford University Press; 1987: 9: 145-149,157.
2. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267-285.
3. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloid polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74: 104-119.
4. Benson MD, Uemichi T. Transthyretin amyloidosis. Amyloid: Int J Exp Clin Invest 1996; 3: 44-56.
5. 30). Clin Genet 1991; 40: 242-246.
6. Holmgren G, Ericzon B-G, Groth C-G, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
7. Steen L, Holmgren G, Suhr O, Wikström L, Groth C-G, Ericzon B-G. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid: Int J Exp Clin Invest 1994; 1: 138-142.
8. Hawkins PN, Myers MJ, Lavender JP, Pepys MB. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1988; I: 1413-1418.
9. 123I-labeled serum amyloid P component. N Engl J Med 1990; 323: 508-513.
10. Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med 1995; 22: 595-599.
11. Hawkins PN. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci 1994; 87: 289-295.
12. Holmgren G, Holmberg E, Lindström A, Lindström E, Nordenson I, Sandgren O, Steen L, Svensson B, Lundgren E, von Gabain A. Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin Genet 1988;33:176-180.
13. Suhr O, Danielsson Å, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994;235:479-485.
14. Reay P. Use of N-bromosuccinimide for the iodination of proteins for radioimmunoassay. Ann Clin Biochem 1982; 19: 129-133.
15. Hawkins PN, Tennent GA, Woo P, Pepys MB. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 1991; 84: 308-316.
16. Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Med 1997; 3: 855-859.
17. Vigushin DM, Pepys MB, Hawkins PN. Comparison of histology with SAP scintigraphy for evaluation of amyloidosis. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds. Amyloid and amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 685-687.
18. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P component (SAP) by amyloid fibrils. Clin Exp Immunol 1979; 38: 284-293.
19. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990; 86: 1862-1869.
20. Hawkins PN, Richardson S, Vigushin DM, David J, Kelsey CR, Gray RES, Hall MA, Woo P, Lavender JP, Pepys MB. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 842-851.
21. Hawkins PN, Richardson S, MacSweeney JE, King AD, Vigushin DM, Lavender JP, Pepys MB. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 1993; 86: 365-374.
22. Hawkins PN, Vigushin DM, Richardson S, Seymour A, Pepys MB. Evaluation of 100 cases of systemic AL amyloidosis by serum amyloid P component (SAP) scintigraphy. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ, Young ID, eds. Amyloid and Amyloidosis 1993. Pearl River, New York: Parthenon Publishing; 1994: 209-211.